Compounds > N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide

Page last updated: 2024-08-03 12:20:40

N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide

Description

N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide : no description available [CHeBI]

Cross-References

ID Source	ID
PubMed CID	25124816
CHEMBL ID	466397
SCHEMBL ID	309890
CHEBI ID	91401

Synonyms (49)

Synonym
gsk1904529a ,
HY-10524
gsk 1904529a
n-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide
bdbm50256480
CHEMBL466397 ,
A24618
igf-ir, igf-iir inhibitor;n-(2,6-difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide;gsk 4529
1089283-49-7
gsk 1904529a (gsk 4529)
EX-8674
gsk-1904529a
NCGC00253439-01
n-(2,6-difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide
S1093
BRD-K04833372-001-01-3
SCHEMBL309890
smr004702770
MLS006010966
n-(2,6-difluorophenyl)-5-(3-{2-[(5-ethyl-2-(methyloxy)-4-{4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl}phenyl)amino]-4-pyrimidinyl}imidazo[1,2-a]pyridin-2-yl)-2-(methyloxy)benzamide
MOSKATHMXWSZTQ-UHFFFAOYSA-N ,
n-(2,6-difluorophenyl)-5-(3-(2-((5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide
AC-28459
n-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl]-2-methoxybenzamide
J-522846
n-(2,6-difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimid inyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide
n-(2,6-difluorophenyl)-5-{3-[2-(5-ethyl-4-{4-[4-(methanesulfonyl)piperazin-1-yl]piperidin-1-yl}-2-methoxyanilino)pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl}-2-methoxybenzamide
DTXSID70648776
EX-A008
CHEBI:91401
AKOS030238962
n-(2,6-difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-
HMS3654G19
gsk 4529
mfcd17010271
NCGC00253439-04
igf-1r inhibitor gs1904529a
SW219610-1
FT-0733738
Q27163259
n-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide
AS-17030
AMY24202
SB19376
HMS3295G13
CCG-264817
nsc-767951
nsc767951
gsk1904529

Drug Classes (1)

Class	Description
benzamides

Protein Targets (16)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	26.3506	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	5.2300	AID1347411
EWS/FLI fusion protein	Homo sapiens (human)	Potency	20.0716	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	26.3506	AID1347053
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	43.4320	AID686947
Interferon beta	Homo sapiens (human)	Potency	5.2300	AID1347411

Inhibition Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Aurora kinase A	Homo sapiens (human)	IC50	1.5000	AID371620
Epidermal growth factor receptor	Homo sapiens (human)	IC50	5.5000	AID1342328; AID371614
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	IC50	5.5000	AID1342329; AID371616
Insulin receptor	Homo sapiens (human)	IC50	0.0610	AID1342327; AID1342589; AID371613; AID371622
Insulin receptor	Homo sapiens (human)	Ki	0.0013	AID371631
Tyrosine-protein kinase Lck	Homo sapiens (human)	IC50	3.0000	AID371621
Insulin-like growth factor 1 receptor	Homo sapiens (human)	IC50	0.0552	AID1342326; AID1342588; AID1894075; AID371373; AID371374
Insulin-like growth factor 1 receptor	Homo sapiens (human)	Ki	0.0016	AID371630
Serine/threonine-protein kinase B-raf	Homo sapiens (human)	IC50	2.0000	AID371617
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	IC50	25.0000	AID371615
Mitogen-activated protein kinase 14	Homo sapiens (human)	IC50	11.0000	AID371619
Aurora kinase B	Homo sapiens (human)	IC50	4.5000	AID371618

Bioassays (68)

Assay ID	Title	Year	Journal	Article
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 ISSN: 1464-3405	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1894075	Inhibition of IGF1R (unknown origin)	2021	Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 ISSN: 1520-4804	Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
AID371616	Inhibition of ErbB2	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371636	Clearance in Beagle dog at 7.2 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371621	Inhibition of LCK	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371637	Volume of distribution at steady state in Beagle dog at 7.2 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371630	Binding affinity to IGF1R by liquid scintillation counting	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371373	Inhibition of GST-tagged IGF1R (957-1367) expressed in baculovirus by time-resolved fluorescence assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371634	Dose normalized AUC in Sprague-Dawley rat at 3 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371629	Antiproliferative activity against HFF cells after 72 hrs by Celltiter assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371617	Inhibition of B-raf V600E mutant	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371619	Inhibition of p38alpha	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371643	Oral bioavailability in cynomolgus monkey at 2.1 mg/kg	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371624	Antiproliferative activity against human LP-1 cells after 72 hrs by Celltiter assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371640	Clearance in cynomolgus monkey at 2.1 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371623	Antiproliferative activity against human NCI-H929 cells after 72 hrs by Celltiter assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371615	Inhibition of ErbB4	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371633	Volume of distribution at steady state in Sprague-Dawley rat at 3 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371618	Inhibition of Aurora B	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371631	Binding affinity to insulin receptor by liquid scintillation counting	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371639	Oral bioavailability in Beagle dog at 7.2 mg/kg	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371627	Antiproliferative activity against human COLO205 cells after 72 hrs by Celltiter assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371628	Antiproliferative activity against human A549 cells after 72 hrs by Celltiter assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371620	Inhibition of Aurora A	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371374	Inhibition of human IGF1R autophosphorylation in transfected mouse NIH3T3 cells	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371635	Oral bioavailability in Sprague-Dawley rat at 3 mg/kg	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371638	Dose normalized AUC in Beagle dog at 7.2 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371632	Clearance in Sprague-Dawley rat at 3 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371626	Antiproliferative activity against human SK-ES cells after 72 hrs by Celltiter assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371622	Inhibition of human insulin receptor autophosphorylation in transfected mouse NIH3T3 cells	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371625	Antiproliferative activity against human TC71 cells after 72 hrs by Celltiter assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371614	Inhibition of EGFR	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371641	Volume of distribution at steady state in cynomolgus monkey at 2.1 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371642	Dose normalized AUC in cynomolgus monkey at 2.1 mg/kg, po	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID371613	Inhibition of GST-tagged insulin receptor expressed in baculovirus by time-resolved fluorescence assay	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 ISSN: 1464-3405	Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.

Research

Studies (19)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (10.53)	29.6817
2010's	9 (47.37)	24.3611
2020's	8 (42.11)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.26%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (94.74%)	84.16%

Substance	Classes	Roles	Relationship Strength
3-aminobenzamide	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	low
dan 2163	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic	low
benzamide	benzamides		low
bromopride	benzamides		low
ci 994	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	low
cisapride	benzamides		low
2-hexyloxybenzamide	aromatic ether; benzamides	antifungal agent	low
itopride	benzamides		low
labetalol	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound		low
lorglumide	benzamides; dicarboxylic acid monoamide; dichlorobenzene; glutamic acid derivative		low
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
metoclopramide	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic	low
moclobemide	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic	low
entinostat	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
deet	benzamides; monocarboxylic acid amide	environmental contaminant; insect repellent; xenobiotic	low
acecainide	acetamides; benzamides	anti-arrhythmia drug	low
nemonapride	benzamides; monochlorobenzenes; monomethoxybenzene; N-alkylpyrrolidine; secondary amino compound; secondary carboxamide; substituted aniline		low
niclosamide	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor	low
picotamide	benzamides		low
procainamide	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker	low
procarbazine	benzamides; hydrazines	antineoplastic agent	low
proglumetacin	aromatic ether; benzamides; carboxylic ester; monochlorobenzenes; N-acylindole; N-alkylpiperazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; lipoxygenase inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug	low
proglumide	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite	low
imatinib	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	low
sulpiride	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist	low
tiapride	benzamides		low
trimethobenzamide	benzamides; tertiary amino compound	antiemetic	low
troxipide	benzamides		low
zm 336372	benzamides		low
iodohippuric acid	benzamides; N-acylglycine; organoiodine compound		low
benzoylarginine-2-naphthylamide	arginine derivative; benzamides; N-(2-naphthyl)carboxamide		low
4-(benzoylamino)-2-hydroxybenzoic acid	benzamides		low
ameltolide	benzamides		low
antimycin a	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide	low
rebemide	benzamides		low
2,6-dichlorobenzamide	benzamides; dichlorobenzene	herbicide; marine xenobiotic metabolite	low
fluorophene	benzamides		low
2-toluanilide	benzamides; benzanilide fungicide		low
2-bromo-N-phenylbenzamide	benzamides		low
xipamide	benzamides		low
capobenic acid	benzamides		low
pronamide	benzamides; dichlorobenzene; terminal acetylenic compound	agrochemical; herbicide	low
clanobutin	benzamides		low
nitazoxanide	benzamides; carboxylic ester		low
Flamprop	benzamides		low
N-[4-(dimethylamino)phenyl]-3,4,5-trimethoxybenzamide	benzamides		low
endralazine	benzamides		low
flutolanil	(trifluoromethyl)benzenes; aromatic ether; benzamides; benzanilide fungicide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor	low
encainide	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker	low
nelfinavir	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor	low
n-benzoylpiperidine	benzamides; N-acylpiperidine		low
pancopride	benzamides		low
octylonium	benzamides		low
parsalmide	benzamides		low
isoxaben	benzamides; isoxazoles	cellulose synthesis inhibitor; herbicide	low
4-aminobenzamide	benzamides		low
4-Methoxybenzamide	benzamides		low
benzoyltyrosine ethyl ester	benzamides; ethyl ester; L-tyrosine derivative; phenols	chromogenic compound	low
salifungin	benzamides		low
n-benzoyl-l-arginine	benzamides; N-acyl-L-arginine		low
gr 127935	1,2,4-oxadiazole; benzamides; N-alkylpiperazine; N-arylpiperazine		low
zacopride	benzamides		low
mozavaptan	benzamides	aquaretic	low
mosapride	aromatic ether; benzamides; monochlorobenzenes; monofluorobenzenes; morpholines; secondary carboxamide; substituted aniline; tertiary amino compound		low
zoxamide	alpha-chloroketone; benzamides; dichlorobenzene		low
procainamide 4-hydroxylamine	benzamides; hydroxylamines	drug metabolite	low
ly 188544	benzamides		low
gr 55562	benzamides		low
n-(2,6-dimethylphenyl)-4-(((diethylamino)acetyl)amino)benzamide	benzamides		low
tariquidar	benzamides		low
n-benzoyltyrosine	benzamides; N-acyl-L-tyrosine		low
rp 73401	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor	low
brovanexine	benzamides		low
aminopotentidine	aromatic ether; benzamides; guanidines; nitrile; piperidines; substituted aniline	H2-receptor antagonist	low
asperphenamate	benzamides; carboxylic ester; L-phenylalanine derivative	antineoplastic agent	low
N-(3-fluorophenyl)benzamide	benzamides		low
benzoylphenylalanine	benzamides; N-acyl-amino acid		low
2-methoxy-N-[2-(methylthio)phenyl]benzamide	benzamides		low
2-(4-fluorobenzoylamino)benzoic acid methyl ester	benzamides		low
xv 638	1,3-thiazoles; benzamides; diazepanone; diol; secondary alcohol; secondary carboxamide; ureas	HIV protease inhibitor	low
roflumilast	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor	low
2-(3-benzamidophenoxy)acetic acid	benzamides		low
ck-0944666	benzamides; indoles; organofluorine compound	actin polymerisation inhibitor	low
gw9662	benzamides		low
N-[2-(1-cyclohexenyl)ethyl]-4-(4-morpholinylmethyl)benzamide	benzamides		low
2-methoxy-N-[6-(1-oxobutylamino)-3-pyridinyl]benzamide	benzamides		low
N-[4-chloro-2-[(2,4-dimethoxyanilino)-oxomethyl]phenyl]-2-furancarboxamide	benzamides		low
[3-[3-(5-methyl-2-furanyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-phenylmethanone	benzamides; N-acylpiperidine		low
4-methyl-N-[2-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]phenyl]benzamide	benzamides		low
N-[2-(2-ethyl-5-tetrazolyl)phenyl]-3-(1-tetrazolyl)benzamide	benzamides		low
N-[2-(2-ethyl-5-tetrazolyl)phenyl]-4-(1-tetrazolyl)benzamide	benzamides		low
N-[2,5-diethoxy-4-[[oxo-(3,4,5-trimethoxyphenyl)methyl]amino]phenyl]-2-furancarboxamide	benzamides		low
(2,4-difluorophenyl)-[3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone	benzamides; N-acylpiperidine		low
2-ethoxy-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide	benzamides		low
4-methyl-N-(2-methyl-5-tetrazolyl)benzamide	benzamides		low
N-[2,5-dimethoxy-4-[[2-(4-morpholinyl)-1-oxoethyl]amino]phenyl]benzamide	benzamides		low
N-(4-fluorophenyl)-4-(2-oxolanylmethylsulfamoyl)benzamide	benzamides		low
azidopine	benzamides		low
4-methoxy-N1,N3-bis(3-pyridinyl)benzene-1,3-dicarboxamide	benzamides		low
2,3,4,5,6-pentafluoro-N-(phenylmethyl)benzamide	benzamides		low
N-(1,1-dioxo-3-thiolanyl)-N-(thiophen-2-ylmethyl)benzamide	benzamides		low
N-(3-methoxyphenyl)-2-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]benzamide	benzamides		low
2-[[(4-acetyloxy-3-methoxyphenyl)-oxomethyl]amino]-5-hydroxybenzoic acid	benzamides		low
N-(3-acetamidophenyl)-4-methoxybenzamide	benzamides		low
N-(3-acetamidophenyl)-3-chlorobenzamide	benzamides		low
4-methoxy-N-(5-methyl-3-isoxazolyl)benzamide	benzamides		low
4-tert-butyl-N-[4-(4-morpholinyl)phenyl]benzamide	benzamides		low
N-(2-fluorophenyl)-4-phenylmethoxybenzamide	benzamides		low
4-methyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzamide	benzamides		low
4-methyl-N-[4-(4-morpholinyl)phenyl]benzamide	benzamides		low
4-methoxy-N-(3-pyridinylmethyl)benzamide	benzamides		low
2-methoxy-N-(2-pyridinyl)benzamide	benzamides		low
N-[3-(4-oxo-3,1-benzoxazin-2-yl)phenyl]benzamide	benzamides		low
N-[(4-pyrimidinylthio)methyl]benzamide	benzamides		low
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-methoxybenzamide	benzamides		low
N-(4-acetamidophenyl)-2-bromobenzamide	benzamides		low
N-(5-acetyl-4-methyl-2-thiazolyl)-4-tert-butylbenzamide	benzamides		low
N-(5-acetyl-4-methyl-2-thiazolyl)-2-methylbenzamide	benzamides		low
2-ethoxy-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]benzamide	benzamides		low
N-(3,4-dimethoxyphenyl)-4-methoxybenzamide	benzamides		low
N-[2-[(4-methylanilino)-oxomethyl]phenyl]-3-pyridinecarboxamide	benzamides		low
N-[4-(2,5-dimethyl-1-pyrrolyl)phenyl]benzamide	benzamides		low
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-methoxybenzamide	benzamides		low
N-[4-(2-methyl-4-thiazolyl)phenyl]benzamide	benzamides		low
N-(3-acetamidophenyl)-2-chlorobenzamide	benzamides		low
3-ethoxy-N-(2-thiazolyl)benzamide	benzamides		low
2-bromo-N-(3-methoxyphenyl)benzamide	benzamides		low
N-(2,4-difluorophenyl)-3-methoxybenzamide	benzamides		low
4-[[(4-acetyloxy-3-methoxyphenyl)-oxomethyl]amino]benzoic acid	benzamides		low
acetic acid [4-[(4-hydroxyanilino)-oxomethyl]-2-methoxyphenyl] ester	benzamides		low
N-(4-benzamido-2-chlorophenyl)-2-furancarboxamide	benzamides		low
2-(hydroxymethyl)-N-(phenylmethyl)benzamide	benzamides		low
2-[[(3-methylphenyl)-oxomethyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylic acid	benzamides		low
2-chloro-4-methyl-N-[4-(4-methyl-1-piperazinyl)phenyl]benzamide	benzamides		low
2-ethoxy-N-(2-hydroxyphenyl)benzamide	benzamides		low
3-[[(3-chloro-4-ethoxyphenyl)-oxomethyl]amino]benzoic acid	benzamides		low
2-methoxy-N-(4-methylphenyl)-4-(methylthio)benzamide	benzamides		low
3-[[(4-methoxyphenyl)-oxomethyl]amino]-2-thiophenecarboxylic acid methyl ester	benzamides		low
2-methoxy-3-methyl-N-[4-(4-morpholinylmethyl)phenyl]benzamide	benzamides		low
N-(4-anilinophenyl)-3,4-dimethoxybenzamide	benzamides		low
N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-4-methylbenzamide	benzamides		low
N-[[(6-methyl-4-pyrimidinyl)thio]methyl]benzamide	benzamides		low
N-(3-acetamidophenyl)-2-methoxybenzamide	benzamides		low
2-bromo-N-[3-(1-oxopropylamino)phenyl]benzamide	benzamides		low
N-(3-acetylphenyl)-3-ethoxybenzamide	benzamides		low
2-[[(3-bromophenyl)-oxomethyl]amino]-5-hydroxybenzoic acid	benzamides		low
1-azepanyl-[4-[(phenylthio)methyl]phenyl]methanone	benzamides		low
4-chloro-N-[4-(2-imidazo[1,2-a]pyridinyl)phenyl]benzamide	benzamides		low
3,4,5-triethoxy-N-(1H-1,2,4-triazol-5-yl)benzamide	benzamides		low
3-[[[3-(4-methoxyphenyl)phenyl]-oxomethyl]amino]benzoic acid	benzamides		low
3-[(4-ethoxyphenoxy)methyl]-N,N-diethylbenzamide	benzamides		low
2-[[anilino(oxo)methyl]amino]-N-(phenylmethyl)benzamide	benzamides		low
4-tert-butyl-N-(4-methyl-3-nitrophenyl)benzamide	benzamides		low
N-(3-methoxyphenyl)-4-[(2-methyl-1-oxopropyl)amino]benzamide	benzamides		low
N-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-3,4,5-trimethoxybenzamide	benzamides		low
4-chloro-3-[[(2-methyl-3-nitrophenyl)-oxomethyl]amino]benzoic acid methyl ester	benzamides		low
N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-nitrobenzamide	benzamides		low
N-(4-methoxyphenyl)-2-(methylthio)benzamide	benzamides		low
N-[3-[[(3,5-dimethoxyphenyl)-oxomethyl]amino]phenyl]carbamic acid ethyl ester	benzamides		low
2,4-dimethyl-N-[4-(1-pyrrolidinyl)phenyl]benzamide	benzamides		low
N-(7-bromo-3,4-dihydro-2H-1,5-benzodioxepin-8-yl)-3-methoxybenzamide	benzamides		low
5-chloro-N-(2-furanylmethyl)-2-[[(4-methoxyphenyl)-oxomethyl]amino]benzamide	benzamides		low
4-[(2-bromophenoxy)methyl]-N-[4-[(3,5-dimethyl-1-pyrazolyl)methyl]phenyl]benzamide	benzamides		low
3-bromo-5-ethoxy-N-(4-fluorophenyl)-4-methoxybenzamide	benzamides		low
2-chloro-N-[3-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-5-(1,2,4-triazol-4-yl)benzamide	benzamides		low
3-[[(3,5-dichloro-4-ethoxyphenyl)-oxomethyl]amino]benzoic acid	benzamides		low
4-[4-[[(3,4-dimethylphenyl)-oxomethyl]amino]phenoxy]phthalic acid	benzamides		low
5-ethyl-2-[[oxo-(3,4,5-trimethoxyphenyl)methyl]amino]-3-thiophenecarboxylic acid ethyl ester	benzamides		low
2-bromo-N-[3-(1-oxobutylamino)phenyl]benzamide	benzamides		low
3-chloro-N-[3-nitro-5-(2-pyridinylthio)phenyl]benzamide	benzamides		low
N-[4-chloro-2-[(2-ethoxyanilino)-oxomethyl]phenyl]-2-furancarboxamide	benzamides		low
4-[[[3-(4-morpholinylsulfonyl)phenyl]-oxomethyl]amino]benzoic acid ethyl ester	benzamides		low
3,4-dimethoxy-N-[4-[oxo(1-piperidinyl)methyl]phenyl]benzamide	benzamides		low
2-fluoro-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]benzamide	benzamides		low
N-(4-benzamido-3-methylphenyl)-1,3-benzodioxole-5-carboxamide	benzamides		low
N-(3-benzamidophenyl)-1,3-benzodioxole-5-carboxamide	benzamides		low
N-[2,2-dichloro-1-(4-chlorophenyl)sulfonylethenyl]benzamide	benzamides		low
2-[[[3-[2-(4-methylphenyl)sulfonylethylthio]phenyl]-oxomethyl]amino]benzoic acid	benzamides		low
4-chloro-N-[3-chloro-4-(4-morpholinyl)phenyl]benzamide	benzamides		low
N-(3-methoxyphenyl)-4-(1-oxopropylamino)benzamide	benzamides		low
N-[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]-4-methylbenzamide	benzamides		low
[2-methoxy-4-(methylthio)phenyl]-[4-(phenylmethyl)-1-piperidinyl]methanone	benzamides; N-acylpiperidine		low
N-[2,5-diethoxy-4-[[(3-methoxyanilino)-sulfanylidenemethyl]amino]phenyl]-4-methylbenzamide	benzamides		low
N-[4-[[anilino(sulfanylidene)methyl]amino]-2,5-diethoxyphenyl]-4-methoxybenzamide	benzamides		low
N-[4-[[anilino(sulfanylidene)methyl]amino]-2,5-diethoxyphenyl]benzamide	benzamides		low
2-(4-chloro-3-methylphenoxy)acetic acid [4-[(4-methylanilino)-oxomethyl]phenyl] ester	benzamides		low
2-(3-chlorophenoxy)acetic acid [4-[(4-methylanilino)-oxomethyl]phenyl] ester	benzamides		low
2-(4-chloro-2-methylphenoxy)acetic acid [4-[(4-methylanilino)-oxomethyl]phenyl] ester	benzamides		low
3-(1,3-dioxo-2-isoindolyl)propanoic acid [4-[(4-methylanilino)-oxomethyl]phenyl] ester	benzamides		low
5-bromo-2-furancarboxylic acid (3-benzamidophenyl) ester	benzamides		low
(4-ethoxyphenyl)-[4-[(4-ethoxyphenyl)-oxomethyl]-1,4-diazepan-1-yl]methanone	benzamides		low
[4-[(2-bromophenoxy)methyl]phenyl]-(1-piperidinyl)methanone	benzamides; N-acylpiperidine		low
3-[(4-bromophenoxy)methyl]-N-(5-methyl-3-isoxazolyl)benzamide	benzamides		low
3-methyl-N-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]benzamide	benzamides		low
N-[4-[methyl(phenyl)sulfamoyl]phenyl]benzamide	benzamides		low
N-[4-[(N-methylanilino)-oxomethyl]phenyl]-2-furancarboxamide	benzamides		low
3-[[[3-(1-azepanylsulfonyl)-4-chlorophenyl]-oxomethyl]amino]benzoic acid	benzamides		low
2-[2-nitro-4-(trifluoromethyl)phenoxy]-N-phenylbenzamide	benzamides		low
4-chloro-N-[2-(4-methylsulfonyl-1-piperazinyl)phenyl]benzamide	benzamides		low
2-[[[(4-methoxyphenyl)-oxomethyl]amino]methyl]-5-phenyl-3-furancarboxylic acid	benzamides		low
N-(3,5-dichlorophenyl)-2-(methanesulfonamido)benzamide	benzamides		low
N-(5-chloro-2-methylphenyl)-4-[(4-chloro-1-pyrazolyl)methyl]benzamide	benzamides		low
2-[[2-[(4-chlorophenyl)thio]-1-oxoethyl]amino]-N-(4-methoxyphenyl)benzamide	benzamides		low
4-methoxy-N-[2-(4-morpholinyl)phenyl]-3-nitrobenzamide	benzamides		low
2-bromo-N-[4-(4-methyl-1-piperazinyl)phenyl]benzamide	benzamides		low
N-[4-[[[(5-bromo-2-furanyl)-oxomethyl]hydrazo]-oxomethyl]phenyl]benzamide	benzamides		low
5-bromo-2-methoxy-3-methyl-N-[4-(4-methylsulfonyl-1-piperazinyl)phenyl]benzamide	benzamides		low
4-methoxy-N-[4-[[(1-oxopropylamino)-sulfanylidenemethyl]amino]phenyl]benzamide	benzamides		low
2-[[(3,5-dimethoxyphenyl)-oxomethyl]amino]-4,5-dimethoxybenzoic acid methyl ester	benzamides		low
2,4,5-trimethoxy-N-(2-phenylphenyl)benzamide	benzamides		low
3-ethoxy-N-[3-(5-phenyl-1,3,4-oxadiazol-2-yl)phenyl]benzamide	benzamides		low
2-[[[3-methyl-4-[[2-(3-nitrophenoxy)-1-oxoethyl]amino]phenyl]-oxomethyl]amino]benzoic acid	benzamides		low
4-methyl-N-[2-methyl-1,3-bis[(4-methyl-1,2,5-oxadiazol-3-yl)oxy]propan-2-yl]benzamide	benzamides		low
[4-[(2,4-dichlorophenoxy)methyl]phenyl]-(4-methyl-1-piperazinyl)methanone	benzamides		low
N-(2-furanylmethyl)-2-[[[2-[(4-methylphenyl)sulfonyl-(phenylmethyl)amino]phenyl]-oxomethyl]amino]benzamide	benzamides		low
2-[(2-cyanophenyl)thio]-N-[4-[dimethylamino(oxo)methyl]phenyl]benzamide	benzamides		low
N-(2-furanylmethyl)-2-[[oxo-(3,4,5-trimethoxyphenyl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	benzamides		low
N-[3-[[(4-nitrophenyl)-oxomethyl]amino]phenyl]-2-furancarboxamide	benzamides		low
N-[(3-benzamidoanilino)-sulfanylidenemethyl]-2-thiophenecarboxamide	benzamides		low
3-chloro-N-[4-[(1-oxo-2-phenylethyl)amino]phenyl]benzamide	benzamides		low
N-(3,4-dimethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)methyl]benzamide	benzamides		low
4-cyano-N-methyl-N-[5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl]benzamide	benzamides		low
4-tert-butyl-N-[2,5-dimethoxy-4-[[1-oxo-2-(1-piperidinyl)ethyl]amino]phenyl]benzamide	benzamides		low
(2,6-difluorophenyl)-[4-(5-fluoro-2-methyl-1-benzimidazolyl)-1-piperidinyl]methanone	benzamides; N-acylpiperidine		low
4-chloro-N-[3-cyano-4-(phenylthio)phenyl]benzamide	benzamides		low
(4-chlorophenyl)-[4-[[(2,4-dichlorophenyl)thio]methyl]-4-hydroxy-1-piperidinyl]methanone	benzamides; N-acylpiperidine		low
N-(4-bromo-2,6-dimethylphenyl)-2-methoxybenzamide	benzamides		low
4-[[(3,6-dichloro-2-methoxyphenyl)-oxomethyl]amino]benzoic acid propyl ester	benzamides		low
N-(2,4-dichlorophenyl)-4-phenylbenzamide	benzamides		low
4-butoxy-N-[4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]phenyl]benzamide	benzamides		low
fm19g11	benzamides		low
N-[4-[(4,6-dimethyl-2-pyrimidinyl)sulfamoyl]phenyl]-2-nitrobenzamide	benzamides		low
3-[(2,5-dichlorophenoxy)methyl]-N-(2,6-dimethylphenyl)benzamide	benzamides		low
2-[[[(3-methyl-1-oxobutyl)amino]-sulfanylidenemethyl]amino]-N-phenylbenzamide	benzamides		low
acetic acid [4-[[3-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]anilino]-oxomethyl]phenyl] ester	benzamides		low
4-[[(4-tert-butylphenyl)-oxomethyl]amino]-3-methyl-2-sulfanylidene-5-thiazolecarboxylic acid ethyl ester	benzamides		low
3-methoxy-N-(2,3,4-trifluorophenyl)benzamide	benzamides		low
2-phenylacetic acid [2-[4-[(4-ethoxyanilino)-oxomethyl]anilino]-2-oxoethyl] ester	benzamides		low
4-[[(2-nitrophenyl)-oxomethyl]amino]benzoic acid propyl ester	benzamides		low
2-[[oxo-(2,3,4,5,6-pentafluorophenyl)methyl]amino]benzoic acid ethyl ester	benzamides		low
2-bromo-N-[3-(1-oxopentylamino)phenyl]benzamide	benzamides		low
4-[(2,4-dichlorophenoxy)methyl]-N-[2-(dimethylamino)ethyl]benzamide	benzamides		low
3-methoxy-N-[2-(3-methoxyphenoxy)ethyl]benzamide	benzamides		low
N-[4-(diethylsulfamoyl)phenyl]-4-(4-morpholinylmethyl)benzamide	benzamides		low
3,5-dimethyl-N-[4-[(1-oxo-2-phenylethyl)amino]phenyl]benzamide	benzamides		low
3-[[[3-[(3-nitrophenyl)sulfamoyl]phenyl]-oxomethyl]amino]benzoic acid	benzamides		low
2-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-(3-methoxyphenyl)benzamide	benzamides		low
4-chloro-3-[(2,5-dimethylphenyl)sulfamoyl]-N-(2-phenylphenyl)benzamide	benzamides		low
4-methyl-N-(2-phenylphenyl)-3-(phenylsulfamoyl)benzamide	benzamides		low
2-[2-[[3-(1,3-benzoxazol-2-yl)anilino]-oxomethyl]phenyl]benzoic acid	benzamides		low
3,4-dimethoxy-N-[4-(2,2,3,3-tetrafluoropropoxy)-3-(trifluoromethyl)phenyl]benzamide	benzamides		low
1-azepanyl-[2-[4-(difluoromethylthio)anilino]phenyl]methanone	benzamides		low
3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester	benzamides		low
2-bromo-N-(4-ethylphenyl)benzamide	benzamides		low
4-amino-N-(2-methoxyphenyl)benzamide	benzamides		low
4-(difluoromethoxy)-N-[5-[[4-(difluoromethylthio)phenyl]methyl]-2-thiazolyl]benzamide	benzamides		low
2-[(4-ethoxyphenyl)sulfonylamino]-N-[2-(4-morpholinyl)phenyl]benzamide	benzamides		low
4-(dimethylamino)-N-[2-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenyl]benzamide	benzamides		low
2-[(2,5-dimethylphenyl)sulfonylamino]-N-[4-(2-pyrimidinylsulfamoyl)phenyl]benzamide	benzamides		low
2-[(5-chloro-2-thiophenyl)sulfonylamino]-N-(2-methoxy-5-methylphenyl)benzamide	benzamides		low
4-methoxy-N-[1-methyl-2-oxo-6-(trifluoromethyl)-3-pyridinyl]benzamide	benzamides		low
N-[4-bromo-3-(trifluoromethyl)phenyl]-2,4,6-trimethylbenzamide	benzamides		low
4-methyl-N-[1-methyl-2-oxo-6-(trifluoromethyl)-3-pyridinyl]benzamide	benzamides		low
4-[2-(4-fluoroanilino)-2-oxoethoxy]-3-methoxy-N-[4-(4-methoxyphenyl)-5-methyl-2-thiazolyl]benzamide	benzamides		low
3-[3-[2-(2-carbamoylphenoxy)-1-oxoethyl]-2,5-dimethyl-1-pyrrolyl]propanoic acid methyl ester	benzamides		low
4-methyl-N-[4-(2-methyl-4-thiazolyl)phenyl]benzamide	benzamides		low
5-(dimethylsulfamoyl)-N-(diphenylmethyl)-2-(1-pyrrolidinyl)benzamide	benzamides		low
2-[(3-fluoro-4-methoxyphenyl)methoxy]benzamide	benzamides		low
N-(4-chloro-2-methoxy-5-methylphenyl)-4-[(3,4-difluorophenyl)sulfonylamino]benzamide	benzamides		low
2-[[(3-methylphenyl)-oxomethyl]amino]benzoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester	benzamides		low
4-(dimethylsulfamoyl)-N-(3-methylphenyl)benzamide	benzamides		low
N-[5-chloro-2-(4-methyl-1-piperazinyl)phenyl]-3-(dimethylsulfamoyl)benzamide	benzamides		low
3-methoxy-N-(4-methyl-2-thiazolyl)benzamide	benzamides		low
3-(diethylsulfamoyl)-N-(3,5-dimethylphenyl)benzamide	benzamides		low
3,4-dimethyl-N-[4-(4-methylpiperazino)benzyl]benzamide	benzamides		low
N-[4-(5-oxazolyl)phenyl]benzamide	benzamides		low
N1-(2,6-dimorpholino-3-pyridyl)-4-methylbenzamide	benzamides		low
2-chloro-N-[3-cyano-4-[(4-methoxyphenyl)thio]phenyl]benzamide	benzamides		low
N-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-3,4-dimethylbenzamide	benzamides		low
sirtinol	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor	low
N-[1-(3-methoxyphenyl)-3-(1-naphthalenylamino)-3-oxopropyl]benzamide	benzamides		low
N-[3-(1-naphthalenylamino)-3-oxo-1-phenylpropyl]benzamide	benzamides		low
4-chloro-3-(diethylsulfamoyl)-N-(2-nitrophenyl)benzamide	benzamides		low
3,4,5-trimethoxy-N-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]benzamide	benzamides		low
N-(4-methoxy-2-nitrophenyl)-3-[(2-methyl-1-oxopropyl)amino]benzamide	benzamides		low
3,4,5-triethoxy-N-[4-(4-methylsulfonyl-1-piperazinyl)phenyl]benzamide	benzamides		low
2-[[[4-[[2-(4-chloro-2-methylphenoxy)-1-oxopropyl]amino]phenyl]-oxomethyl]amino]benzoic acid	benzamides		low
N-(5-chloro-2-hydroxyphenyl)-2-ethoxybenzamide	benzamides		low
N-[2-[(2-furanylmethylamino)-oxomethyl]phenyl]-4-methyl-3-(1-piperidinylsulfonyl)benzamide	benzamides		low
4-methoxy-N-[4-[1-[(4-methoxyanilino)-oxomethyl]cyclopentyl]phenyl]benzamide	benzamides		low
N-[3-chloro-2-(1-piperidinyl)phenyl]-4-(4-morpholinyl)-3-nitrobenzamide	benzamides		low
N-[4-(6-imidazo[2,1-b]thiazolyl)phenyl]-4-methoxy-3-(4-morpholinylsulfonyl)benzamide	benzamides		low
norcisapride	benzamides		low
prucalopride	benzamides		low
Dihydroalatamide	benzamides		low
4-methoxy-N-[2,2,2-trichloro-1-(4-methylanilino)ethyl]benzamide	benzamides		low
N-(2-hydroxy-5-nitrophenyl)-3-nitrobenzamide	benzamides		low
N-[3-(1,3-benzothiazol-2-ylthio)-5-nitrophenyl]-2-fluorobenzamide	benzamides		low
N-[2-[5-[(4-tert-butylphenyl)methylthio]-1,3,4-oxadiazol-2-yl]phenyl]benzamide	benzamides		low
N-butan-2-yl-4-[4-oxo-3-(phenylmethyl)-2-thiazolidinyl]benzamide	benzamides		low
4-[3-(2-furanylmethyl)-4-oxo-2-thiazolidinyl]-N-(3-propan-2-yloxypropyl)benzamide	benzamides		low
2-methyl-N-[1-(4-prop-2-enyl-5-sulfanylidene-1H-1,2,4-triazol-3-yl)ethyl]benzamide	benzamides		low
N-[4-(4-methoxyphenyl)-2-thiazolyl]-N-(2-oxolanylmethyl)benzamide	benzamides		low
3-chloro-4-ethoxy-N-[3-(2-oxazolo[5,4-b]pyridinyl)phenyl]benzamide	benzamides		low
4-[[(3-methoxyphenyl)-oxomethyl]amino]benzoic acid	benzamides		low
3-[[oxo-[3-(1-piperidinylsulfonyl)phenyl]methyl]amino]benzoic acid	benzamides		low
N-(4-ethoxyphenyl)-2-(hydroxymethyl)benzamide	benzamides		low
N-(5-acetyl-2-phenyl-4-sulfanylidene-1H-pyrimidin-6-yl)benzamide	benzamides		low
sb-224289	1,2,4-oxadiazole; azaspiro compound; benzamides; organic heterotetracyclic compound	serotonergic antagonist	low
N-[(4-methylphenyl)methyl]-4-(1-pyrrolyl)benzamide	benzamides		low
1-[(4-chlorophenyl)-oxomethyl]-N-[4-(1-piperidinylsulfonyl)phenyl]-3-piperidinecarboxamide	benzamides; N-acylpiperidine		low
N-(4-bromophenyl)-2-[(5,6-dimethyl-4-thieno[2,3-d]pyrimidinyl)thio]benzamide	benzamides; thienopyrimidine		low
4-(3,5-dimethyl-1-pyrazolyl)-N-[2-methoxy-5-(4-morpholinylsulfonyl)phenyl]benzamide	benzamides		low
N-[5-ethyl-3-[(4-fluorophenyl)-(4-morpholinyl)methyl]-2-thiophenyl]benzamide	benzamides		low
N-cycloheptyl-4-(2-oxolanylmethoxy)benzamide	benzamides		low
2-(4-methoxyphenyl)acetic acid [2-[4-[(4-ethoxyanilino)-oxomethyl]anilino]-2-oxoethyl] ester	benzamides		low
2-methyl-3-nitro-N-[4-[[(1-oxopropylamino)-sulfanylidenemethyl]amino]phenyl]benzamide	benzamides		low
N-[2-(3-methyl-1-oxobutyl)-3-oxo-1,2,4-thiadiazol-5-yl]benzamide	benzamides		low
2-[4-[[(3-chlorophenyl)-oxomethyl]amino]phenyl]propanedioic acid dimethyl ester	benzamides		low
N-(3,5-dimethylphenyl)-2-(2-nitroethyl)benzamide	benzamides		low
N-[4-[[(4-tert-butylphenyl)-oxomethyl]amino]phenyl]-2-furancarboxamide	benzamides		low
N-[3-[(4-ethoxyphenyl)-[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-4,5-dimethyl-2-thiophenyl]benzamide	benzamides		low
2-methoxy-N-(5-phenyl-1,2,4-thiadiazol-3-yl)benzamide	benzamides		low
N-(3-chlorophenyl)-4-fluoro-3-(thiophen-2-ylmethylsulfamoyl)benzamide	benzamides		low
3-acetamido-N-[(4-ethoxy-3-methoxyphenyl)methyl]-4-[(4-methylphenyl)thio]benzamide	benzamides		low
N-[3-(4-morpholinylsulfonyl)phenyl]-4-(2-oxo-1-pyrrolidinyl)benzamide	benzamides		low
N,N-dimethylsulfamic acid [3-[(4-methoxyanilino)-oxomethyl]phenyl] ester	benzamides		low
N-[1-(benzenesulfonyl)-2,2-dichloroethenyl]-4-methylbenzamide	benzamides		low
N-[4-chloro-3-[(4-chlorophenyl)sulfamoyl]phenyl]-4-propan-2-yloxybenzamide	benzamides		low
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
N-[3-[(2-bromo-5-methylphenyl)sulfamoyl]-4-methoxyphenyl]-4-fluorobenzamide	benzamides		low
N-[2,5-diethoxy-4-(4-morpholinyl)phenyl]-4-[(3,5-dimethyl-4-isoxazolyl)methoxy]-3-methoxybenzamide	benzamides		low
4-methyl-N-[2-[(5-oxo-2,3-dihydrothiazolo[2,3-b]quinazolin-3-yl)methylthio]phenyl]benzamide	benzamides		low
4-cyano-N-[4-thiophen-2-yl-5-(2,2,2-trifluoro-1-oxoethyl)-2-thiazolyl]benzamide	benzamides		low
4-(1-azepanylsulfonyl)-N-[5-[(4-chlorophenyl)sulfamoyl]-2-hydroxyphenyl]benzamide	benzamides		low
N-[4-(4-fluorophenyl)-2-thiazolyl]-3-methoxy-4-[2-(4-morpholinyl)-2-oxoethoxy]benzamide	benzamides		low
N-[4-chloro-3-(4-morpholinylsulfonyl)phenyl]-4-(2-oxolanylmethoxy)benzamide	benzamides		low
N-[3-[(4-chlorophenyl)methylthio]-1H-1,2,4-triazol-5-yl]-4-cyanobenzamide	benzamides		low
2-(4-methylphenoxy)-N-[2-[oxo(1-piperidinyl)methyl]phenyl]acetamide	benzamides; N-acylpiperidine		low
imd 0354	benzamides		low
N-(3-chlorophenyl)-3-[ethyl(phenyl)sulfamoyl]-4-fluorobenzamide	benzamides		low
4-tert-butyl-N-[3-[4-[3-[[(4-tert-butylphenyl)-oxomethyl]amino]propyl]-1-piperazinyl]propyl]benzamide	benzamides		low
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide	benzamides		low
4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide	benzamides		low
tiapridex	benzamides		low
[2-methoxy-5-[[4-(4-methylphenyl)-1-phthalazinyl]amino]phenyl]-(1-piperidinyl)methanone	benzamides; N-acylpiperidine		low
axitinib	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	low
4-[(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)methyl]-N-(3-ethylphenyl)benzamide	benzamides		low
LSM-32377	benzamides		low
ispinesib	benzamides		low
fk 866	benzamides; N-acylpiperidine		low
4-acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide	benzamides		low
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone	benzamides; N-acylpiperidine		low
midostaurin	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	low
bms201038	(trifluoromethyl)benzenes; benzamides; fluorenes; piperidines	anticholesteremic drug; MTP inhibitor	low
mocetinostat	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	low
cgp 74588	benzamides		low
zm 447439	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor	low
tak-715	benzamides		low
masitinib	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor	low
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
betrixaban	benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	low
nigerloxin	aromatic ether; benzamides; benzoic acids; phenols; styrenes	antioxidant; Aspergillus metabolite; EC 1.1.1.21 (aldehyde reductase) inhibitor; lipoxygenase inhibitor; radical scavenger	low
myxochelin b	benzamides; catechols	bacterial metabolite; siderophore	low
fluopicolide	benzamide fungicide; benzamides; dichlorobenzene; monochloropyridine; organofluorine compound	antifungal agrochemical	low
eluxadoline	amino acid amide; benzamides; imidazoles; L-phenylalanine derivative; methoxybenzoic acid	delta-opioid receptor antagonist; gastrointestinal drug; kappa-opioid receptor agonist; mu-opioid receptor agonist	low
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide	benzamides		low
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide	benzamides		low
chir 090	acetylenic compound; benzamides; hydroxamic acid; L-threonine derivative; morpholines	antimicrobial agent; EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor; lipopolysaccharide biosynthesis inhibitor	low
ki11502	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
az-628	benzamides		low
at 13387	benzamides; isoindoles; N-alkylpiperazine; resorcinols; tertiary carboxamide	antineoplastic agent; Hsp90 inhibitor	low
4-[[[2-(cyclohexylamino)-3,4-dioxo-1-cyclobutenyl]amino]methyl]-N-(4-ethoxyphenyl)benzamide	benzamides		low
chidamide	benzamides		low
N-(3,5-dichlorophenyl)-4-[(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)methyl]benzamide	benzamides		low
mdv 3100	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent	low
3-nitro-4-(2-oxolanylmethylamino)-N-(2-phenylethyl)benzamide	benzamides		low
2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide	aminopyrimidine; benzamides	protein kinase inhibitor	low
azd 7545	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent	low
N-[3-[2-(4-chloroanilino)-4-thiazolyl]phenyl]-3-(trifluoromethyl)benzamide	benzamides		low
3-(trifluoromethyl)-N-[4-[2-[3-(trifluoromethyl)anilino]-4-thiazolyl]phenyl]benzamide	benzamides		low
2-amino-N-[3-methoxy-5-[oxo-[3-(trifluoromethyl)anilino]methyl]phenyl]-5-oxazolecarboxamide	benzamides		low
2-amino-N-[3-methoxy-5-[oxo-[3-(trifluoromethyl)anilino]methyl]phenyl]-4-thiazolecarboxamide	benzamides		low
2-amino-N-[3-methoxy-5-[oxo-[3-(trifluoromethyl)anilino]methyl]phenyl]-4-pyridinecarboxamide	benzamides		low
3-(4-bromophenyl)-N-[5-[[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)anilino]-oxomethyl]-2-methylphenyl]-1H-pyrazole-5-carboxamide	benzamides		low
N-[3-amino-1-[4-[2-(4-methoxyphenyl)ethylamino]-3-nitrophenyl]-3-oxopropyl]-4-bromobenzamide	benzamides		low
nvp-bhg712	benzamides		low
respirantin	benzamides; cyclodepsipeptide; formamides; phenols	antimicrobial agent; antineoplastic agent; metabolite	low
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide	benzamides		low
ph 797804	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
2-[(6-chloro-3-pyridinyl)sulfonylamino]-N-[(4-methylphenyl)methyl]benzamide	benzamides		low
2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]benzamide	benzamides		low
lde225	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist	low
gdc 0449	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent	low
3-[[1-[1-(methylthio)propan-2-yl]-4-piperidinyl]oxy]-N-(2-pyridinylmethyl)benzamide	benzamides		low
3-[[1-(dimethylsulfamoyl)-4-piperidinyl]oxy]-N-[(3-methyl-5-isoxazolyl)methyl]benzamide	benzamides		low
ponatinib	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor	low
N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide	benzamides; biphenyls; cyclopropanes; dicarboxylic acid diamide	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
4-tert-butyl-N-[5-[[2-oxo-2-(2-oxolanylmethylamino)ethyl]thio]-1,3,4-thiadiazol-2-yl]benzamide	benzamides		low
4-ethoxy-N-[5-[[2-oxo-2-(2-oxolanylmethylamino)ethyl]thio]-1,3,4-thiadiazol-2-yl]benzamide	benzamides		low
GRL-0617	benzamides; naphthalenes; secondary carboxamide; substituted aniline	anticoronaviral agent; protease inhibitor	low
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
entrectinib	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
ixazomib	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor	low
N-(2-chlorophenyl)-4-[[2-[4-[2-(4-ethyl-1-piperazinyl)-2-oxoethyl]anilino]-5-fluoro-4-pyrimidinyl]amino]benzamide	benzamides		low
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-(2-thiazolyl)benzamide	benzamides		low
N-(2-aminophenyl)-4-[[[(2S,3S)-10-[[cyclohexyl(oxo)methyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl-methylamino]methyl]benzamide	benzamides		low
KOM70144	acetamides; benzamides; naphthalenes; secondary carboxamide	anticoronaviral agent; protease inhibitor	low
iwr-1 endo	benzamides; bridged compound; dicarboximide; quinolines	axin stabilizer; Wnt signalling inhibitor	low
ulixacaltamide	benzamides; monochlorobenzenes; monofluorobenzenes; piperidines; secondary carboxamide	non-narcotic analgesic; T-type calcium channel blocker	low
xl765	aromatic amine; aromatic ether; benzamides; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
azd4547	benzamides; N-arylpiperazine; pyrazoles	fibroblast growth factor receptor antagonist	low
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide	benzamides; N-acylpiperidine		low
entecavir	benzamides; N-acylpiperidine		low
acp-196	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
pf-06463922	aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
DDR1-IN-1	(trifluoromethyl)benzenes; aromatic ether; benzamides; N-alkylpiperazine; oxindoles; secondary carboxamide	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
N-[2-methyl-5-[oxo-[3-(1-oxoprop-2-enylamino)-5-(trifluoromethyl)anilino]methyl]phenyl]-5-isoxazolecarboxamide	benzamides		low
PF-06446846	benzamides; monochloropyridine; piperidines; tertiary carboxamide; triazolopyridine	antilipemic drug; EC 3.4.21.61 (kexin) inhibitor	low
5,10-methylenetetrahydrofolic acid	benzamides; methylenetetrahydrofolic acid		low
N-cyclohexyl-3-methyl-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide	benzamides		low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2010's	post-2020
pk 11195	1	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent	2013	2013	11.0	low	1	0
pd 173074	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	2013	2013	11.0	low	1	0
abt 702	1	bipyridines		2013	2013	11.0	low	1	0
bicalutamide	1	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol		2013	2013	11.0	low	1	0
verapamil	1	aromatic ether; nitrile; polyether; tertiary amino compound		2013	2013	11.0	low	1	0
celecoxib	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2013	2013	11.0	low	1	0
chelerythrine	1	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	1	0
chloroquine	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug	2021	2021	3.0	low	0	1
furosemide	1	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic	2013	2013	11.0	low	1	0
gossypol	1			2013	2013	11.0	low	1	0
fasudil	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2013	2013	11.0	low	1	0
indirubin-3'-monoxime	1			2013	2013	11.0	low	1	0
leflunomide	1	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
letrozole	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2013	2013	11.0	low	1	0
lg 100268	1			2013	2013	11.0	low	1	0
metformin	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic	2013	2013	11.0	low	1	0
mitoxantrone	1	dihydroxyanthraquinone	analgesic; antineoplastic agent	2013	2013	11.0	low	1	0
entinostat	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2013	2013	11.0	low	1	0
olprinone	1	bipyridines		2013	2013	11.0	low	1	0
omeprazole	1	aromatic ether; benzimidazoles; pyridines; sulfoxide		2013	2013	11.0	low	1	0
pioglitazone	1	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	2013	2013	11.0	low	1	0
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one	1	indoles		2013	2013	11.0	low	1	0
riluzole	1	benzothiazoles		2013	2013	11.0	low	1	0
sb 206553	1	pyrroloindole		2013	2013	11.0	low	1	0
sb 220025	1	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
sb 202190	1	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
sk&f 86002	1	imidazoles		2013	2013	11.0	low	1	0
imatinib	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
vorinostat	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2013	2013	11.0	low	1	0
sulfasalazine	1			2013	2013	11.0	low	1	0
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine	1	stilbenoid		2013	2013	11.0	low	1	0
troglitazone	1	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent	2013	2013	11.0	low	1	0
azacitidine	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent	2013	2013	11.0	low	1	0
podophyllotoxin	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	2013	2013	11.0	low	1	0
formestane	1	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2013	2013	11.0	low	1	0
hydroxychloroquine sulfate	1			2013	2013	11.0	low	1	0
amiloride hydrochloride, anhydrous	1	hydrochloride	diuretic; sodium channel blocker	2013	2013	11.0	low	1	0
acadesine	1	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor	2013	2013	11.0	low	1	0
cladribine	1	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent	2013	2013	11.0	low	1	0
zidovudine	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor	2013	2013	11.0	low	1	0
lonidamine	1	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector	2013	2013	11.0	low	1	0
paroxetine	1	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor	2021	2021	3.0	low	0	1
simvastatin	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug	2013	2013	11.0	low	1	0
itraconazole	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor	2013	2013	11.0	low	1	0
pravadoline	1			2013	2013	11.0	low	1	0
zileuton	1	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug	2013	2013	11.0	low	1	0
niguldipine	1	diarylmethane		2013	2013	11.0	low	1	0
topotecan	1	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor	2013	2013	11.0	low	1	0
eliprodil	1	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound		2013	2013	11.0	low	1	0
gemcitabine	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	2013	2013	11.0	low	1	0
verapamil hydrochloride	1			2013	2013	11.0	low	1	0
efavirenz	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor	2013	2013	11.0	low	1	0
bendamustine	1	benzimidazoles		2013	2013	11.0	low	1	0
caroverine	1	quinoxaline derivative		2013	2013	11.0	low	1	0
cgs 9343b	1	benzimidazoles		2013	2013	11.0	low	1	0
telmisartan	1	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic	2013	2013	11.0	low	1	0
2-methoxyestradiol	1	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite	2013	2013	11.0	low	1	0
alacepril	1	dipeptide; thioacetate ester	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2013	2013	11.0	low	1	0
ubenimex	1			2013	2013	11.0	low	1	0
vinpocetine	1			2013	2013	11.0	medium	1	0
deguelin	1	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite	2013	2013	11.0	low	1	0
triptolide	1	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite	2013	2013	11.0	low	1	0
sr 48692	1	N-acyl-amino acid		2013	2013	11.0	low	1	0
elacridar	1			2013	2013	11.0	low	1	0
gefitinib	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	2013	2013	11.0	low	1	0
bay x 1005	1			2013	2013	11.0	low	1	0
gyki 53655	1			2013	2013	11.0	low	1	0
ml-3000	1			2013	2013	11.0	low	1	0
cd 437	1	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist	2013	2013	11.0	low	1	0
docetaxel anhydrous	1	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent	2013	2013	11.0	low	1	0
perifosine	1	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
mk 767	1			2013	2013	11.0	low	1	0
bazedoxifene acetate	1			2013	2013	11.0	medium	1	0
canertinib	1	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
birb 796	1	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator	2013	2013	11.0	low	1	0
tipifarnib	1	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	2013	2013	11.0	low	1	0
cyc 202	1	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
sb 203580	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	2013	2013	11.0	low	1	0
enzastaurin	1	indoles; maleimides		2013	2013	11.0	low	1	0
erlotinib	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor	2013	2013	11.0	low	1	0
piboserod	1			2013	2013	11.0	low	1	0
l 163191	1			2013	2013	11.0	low	1	0
bd 1047	1	primary amine		2013	2013	11.0	low	1	0
lapatinib	1	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
sorafenib	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
lenalidomide	1	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator	2013	2013	11.0	low	1	0
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide	1	aminoquinoline		2013	2013	11.0	medium	1	0
sr 142806	1			2013	2013	11.0	low	1	0
elesclomol	1	carbohydrazide; thiocarbonyl compound	antineoplastic agent; apoptosis inducer	2013	2013	11.0	low	1	0
nsc 663284	1	quinolone		2013	2013	11.0	low	1	0
bortezomib	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor	2013	2013	11.0	low	1	0
bardoxolone methyl	1	cyclohexenones		2013	2013	11.0	low	1	0
nsc 23766	1	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist	2013	2013	11.0	low	1	0
gw 3965	1	diarylmethane		2013	2013	11.0	low	1	0
y 27632	2	aromatic amide		2013	2021	7.0	low	1	1
6-bromoindirubin-3'-oxime	1			2013	2013	11.0	low	1	0
purvalanol b	1	purvalanol	protein kinase inhibitor	2013	2013	11.0	low	1	0
y-700	1			2013	2013	11.0	low	1	0
repsox	1	pyrazolopyridine		2013	2013	11.0	low	1	0
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide	1	tropane alkaloid		2013	2013	11.0	medium	1	0
s 1033	1	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
mercaptopurine	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent	2013	2013	11.0	low	1	0
rg108	1	indolyl carboxylic acid		2013	2013	11.0	low	1	0
stf 083010	1			2013	2013	11.0	medium	1	0
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide	1	naphthalenecarboxamide		2013	2013	11.0	low	1	0
cct018159	1	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor	2013	2013	11.0	low	1	0
secinh3	1	triazoles		2013	2013	11.0	low	1	0
jk184	1			2013	2013	11.0	low	1	0
tamoxifen citrate	1	citrate salt	angiogenesis inhibitor; anticoronaviral agent	2013	2013	11.0	low	1	0
hc-067047	1			2013	2013	11.0	low	1	0
bi-78d3	1	aryl sulfide		2013	2013	11.0	low	1	0
gsk 3787	1			2013	2013	11.0	low	1	0
methyl-thiohydantoin-tryptophan	1	organonitrogen compound; organooxygen compound		2013	2013	11.0	low	1	0
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester	1	monocarboxylic acid		2013	2013	11.0	medium	1	0
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide	1	sulfonamide		2013	2013	11.0	low	1	0
LSM-1318	1	oxa-steroid		2013	2013	11.0	low	1	0
rwj 67657	1			2013	2013	11.0	low	1	0
6-methyl-2-(phenylethynyl)pyridine	1	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist	2013	2013	11.0	low	1	0
bms 387032	1	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
tandutinib	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
vx-745	1	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
corlanor	1	hydrochloride	cardiotonic drug	2013	2013	11.0	medium	1	0
dasatinib	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
zd 6474	1	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
compound 968	1	benzophenanthridine	EC 3.5.1.2 (glutaminase) inhibitor	2013	2013	11.0	low	1	0
sb-224289	1	1,2,4-oxadiazole; azaspiro compound; benzamides; organic heterotetracyclic compound	serotonergic antagonist	2013	2013	11.0	low	1	0
gw 7647	1	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist	2013	2013	11.0	low	1	0
l 663536	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist	2013	2013	11.0	low	1	0
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine	1	imidazoles		2013	2013	11.0	medium	1	0
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine	1	aromatic amine; tertiary amino compound		2013	2013	11.0	medium	1	0
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester	1	isoquinolines		2013	2013	11.0	low	1	0
sch 79797	1	quinazolines		2013	2013	11.0	low	1	0
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide	1	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one	1	monobactam		2013	2013	11.0	medium	1	0
imd 0354	1	benzamides		2013	2013	11.0	low	1	0
ex 527	1	carbazoles; monocarboxylic acid amide; organochlorine compound		2013	2013	11.0	low	1	0
quercetin	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger	2013	2013	11.0	low	1	0
genistein	1	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
fenretinide	1	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant	2013	2013	11.0	low	1	0
ter 199	1			2013	2013	11.0	low	1	0
arachidonylcyclopropylamide	1			2013	2013	11.0	low	1	0
ly 320135	1	benzofurans		2013	2013	11.0	low	1	0
pd 166285	1			2013	2013	11.0	low	1	0
kn 62	1	piperazines		2013	2013	11.0	low	1	0
su 6656	1			2013	2013	11.0	low	1	0
bosutinib	1	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor	2021	2021	3.0	low	0	1
semaxinib	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
su 11248	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
palbociclib	1	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
jnj-7706621	1	sulfonamide		2013	2013	11.0	low	1	0
cisplatin	1	diamminedichloroplatinum	antineoplastic agent; apoptosis inducer; cross-linking reagent; ferroptosis inducer; genotoxin; mutagen; nephrotoxin; photosensitizing agent	2013	2013	11.0	low	1	0
vx680	1	N-arylpiperazine		2013	2013	11.0	low	1	0
d 4476	1	imidazoles		2013	2013	11.0	low	1	0
cyc 116	1			2013	2013	11.0	low	1	0
bay 19-8004	1			2013	2013	11.0	low	1	0
axitinib	1	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
pai 039	1	indole-3-acetic acids		2013	2013	11.0	low	1	0
gw2974	1	pyridopyrimidine		2013	2013	11.0	low	1	0
ispinesib	1	benzamides		2013	2013	11.0	low	1	0
temsirolimus	1	macrolide lactam		2013	2013	11.0	low	1	0
pd 184352	1	aminobenzoic acid		2013	2013	11.0	low	1	0
bibx 1382bs	1	substituted aniline		2013	2013	11.0	low	1	0
hdac-42	1	amidobenzoic acid		2013	2013	11.0	low	1	0
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone	1	benzamides; N-acylpiperidine		2013	2013	11.0	low	1	0
iniparib	1	carbonyl compound; organohalogen compound		2013	2013	11.0	low	1	0
mk 0752	1			2013	2013	11.0	low	1	0
gw 501516	1	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist	2013	2013	11.0	low	1	0
av 412	1			2013	2013	11.0	low	1	0
ag-041r	1			2013	2013	11.0	low	1	0
telatinib	1			2013	2013	11.0	low	1	0
y-39983	1	pyrrolopyridine		2021	2021	3.0	low	0	1
cp 547632	1			2013	2013	11.0	low	1	0
spc-839	1			2013	2013	11.0	low	1	0
lenvatinib	1	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
andarine	1	acetamides; anilide		2013	2013	11.0	low	1	0
gw843682x	1	(trifluoromethyl)benzenes		2013	2013	11.0	low	1	0
pd 0325901	1	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	2013	2013	11.0	low	1	0
midostaurin	1	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	1	0
ag 14361	1	benzimidazoles		2013	2013	11.0	low	1	0
sb 265610	1			2013	2013	11.0	low	1	0
ripasudil	1	isoquinolines		2021	2021	3.0	medium	0	1
fr 148083	1	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor	2013	2013	11.0	low	1	0
mocetinostat	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	2013	2013	11.0	low	1	0
osi 930	1	aromatic amide		2013	2013	11.0	low	1	0
ki 20227	1			2013	2013	11.0	low	1	0
scio-469	1	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
ssr 69071	1	pyridopyrimidine		2013	2013	11.0	low	1	0
pi103	1	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2013	2013	11.0	low	1	0
sb 210313	1			2013	2013	11.0	high	1	0
gw 4064	1	stilbenoid		2013	2013	11.0	low	1	0
sa 4503	1			2013	2013	11.0	low	1	0
ic 87114	1	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
zibotentan	1	phenylpyridine		2013	2013	11.0	low	1	0
tivozanib	1	aromatic ether		2013	2013	11.0	low	1	0
hki 272	1	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
tofacitinib	2	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2021	7.0	low	1	1
bibr 1532	1			2013	2013	11.0	low	1	0
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide	1			2013	2013	11.0	low	1	0
rucaparib	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2013	2013	11.0	low	1	0
cediranib	1	aromatic ether		2013	2013	11.0	low	1	0
gw0742	1	monocarboxylic acid		2013	2013	11.0	low	1	0
ps1145	1	beta-carbolines		2013	2013	11.0	low	1	0
bay 41-8543	1	pyrazolopyridine		2013	2013	11.0	low	1	0
chir 99021	1	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	2013	2013	11.0	low	1	0
sb 525334	1	quinoxaline derivative		2013	2013	11.0	low	1	0
way-362450	1	indoles		2013	2013	11.0	low	1	0
masitinib	2	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor	2013	2021	7.0	low	1	1
bx795	1	ureas		2013	2013	11.0	low	1	0
pazopanib	1	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	1	0
sepantronium	1	organic cation		2013	2013	11.0	low	1	0
azd 6244	1	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea	1			2013	2013	11.0	low	1	0
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide	1	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	medium	1	0
ar c155858	1			2013	2013	11.0	low	1	0
aee 788	1	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug	2013	2013	11.0	low	1	0
saracatinib	1	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent	2013	2013	11.0	low	1	0
sd-208	1			2013	2013	11.0	low	1	0
vx 702	1	phenylpyridine		2013	2013	11.0	low	1	0
volasertib	1			2013	2013	11.0	low	1	0
PB28	1	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist	2013	2013	11.0	low	1	0
azd 7762	1	aromatic amide; thiophenes		2013	2013	11.0	low	1	0
krp-203	1			2013	2013	11.0	low	1	0
mk 0354	1			2013	2013	11.0	low	1	0
regorafenib	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester	1	pyrroloquinoline		2013	2013	11.0	low	1	0
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	2	methoxybenzenes; substituted aniline		2013	2021	7.0	low	1	1
brivanib	1	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	2013	2013	11.0	low	1	0
icg 001	1	peptide		2013	2013	11.0	low	1	0
mp470	1	N-arylpiperazine		2013	2013	11.0	low	1	0
np 031112	1	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2021	2021	3.0	low	0	1
nu 7441	1	dibenzothiophenes		2013	2013	11.0	low	1	0
at 7519	1	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	1	0
bi 2536	1			2013	2013	11.0	low	1	0
danusertib	1	piperazines		2013	2013	11.0	low	1	0
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide	1	benzamides		2013	2013	11.0	low	1	0
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide	1	benzamides		2013	2013	11.0	low	1	0
abt 869	1	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
dorsomorphin	1	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor	2013	2013	11.0	low	1	0
ac 261066	1			2013	2013	11.0	low	1	0
carfilzomib	1	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor	2013	2013	11.0	low	1	0
gw9508	1	aromatic amine		2013	2013	11.0	low	1	0
jnj 26854165	1			2013	2013	11.0	low	1	0
pf 573228	2	quinolines		2013	2021	7.0	low	1	1
gw 2580	1			2013	2013	11.0	low	1	0
idelalisib	1	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
crizotinib	1	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile	1	benzimidazoles		2013	2013	11.0	low	1	0
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide	1	aromatic amide; heteroarene		2013	2013	11.0	low	1	0
osi 906	1	cyclobutanes; quinolines		2013	2013	11.0	low	1	0
ly2109761	1			2013	2013	11.0	low	1	0
chir-265	1	aromatic ether		2013	2013	11.0	low	1	0
motesanib	1	pyridinecarboxamide		2013	2013	11.0	low	1	0
az-628	1	benzamides		2013	2013	11.0	low	1	0
trametinib	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2013	2013	11.0	low	1	0
pf-562,271	1	indoles		2013	2013	11.0	low	1	0
pha 767491	1	pyrrolopyridine		2021	2021	3.0	low	0	1
veliparib	1	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2013	2013	11.0	low	1	0
ku-0060648	1	dibenzothiophenes		2013	2013	11.0	low	1	0
dactolisib	1	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2013	2013	11.0	low	1	0
palomid 529	1			2013	2013	11.0	low	1	0
tosedostat	1	carboxylic ester; hydroxamic acid; secondary carboxamide		2013	2013	11.0	low	1	0
mdv 3100	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent	2013	2013	11.0	low	1	0
ku 60019	1			2013	2013	11.0	low	1	0
gsk 461364	1	(trifluoromethyl)benzenes		2013	2013	11.0	low	1	0
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide	1			2013	2013	11.0	low	1	0
nvp-tae684	1	piperidines		2013	2013	11.0	low	1	0
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide	1			2013	2013	11.0	medium	1	0
gsk 269962a	1			2013	2013	11.0	low	1	0
a-83-01	1			2013	2013	11.0	low	1	0
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one	1	indoles		2013	2013	11.0	medium	1	0
vx-770	1	aromatic amide; monocarboxylic acid amide; phenols; quinolone	CFTR potentiator; orphan drug	2013	2013	11.0	low	1	0
buparlisib	1	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
azd 1480	1			2013	2013	11.0	low	1	0
fedratinib	2	sulfonamide		2013	2021	7.0	low	1	1
gsk690693	1	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	2013	2013	11.0	low	1	0
cnf 2024	1	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor	2013	2013	11.0	low	1	0
ku 0063794	1	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor	2013	2013	11.0	low	1	0
azd 7545	1	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent	2013	2013	11.0	low	1	0
nutlin-3b	1	Nutlin; piperazinone	anticoronaviral agent	2013	2013	11.0	low	1	0
pf 04217903	1	quinolines		2013	2013	11.0	low	1	0
gdc 0941	1	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
sm 164	1	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent	2013	2013	11.0	low	1	0
ph 797804	1	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	1	0
pha 408	1			2013	2013	11.0	low	1	0
gsk 1016790a	1	1-benzothiophenes; aromatic primary alcohol; dichlorobenzene; N-acylpiperazine; sulfonamide; tertiary carboxamide	TRPV4 agonist	2013	2013	11.0	low	1	0
olaparib	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2013	2013	11.0	low	1	0
srt1720	1			2013	2013	11.0	low	1	0
plx 4720	1	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor	2013	2013	11.0	low	1	0
cx 4945	1			2013	2013	11.0	low	1	0
cudc 101	1			2013	2013	11.0	low	1	0
mln 8237	1	benzazepine		2013	2013	11.0	low	1	0
lde225	1	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist	2013	2013	11.0	low	1	0
gdc 0449	1	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent	2013	2013	11.0	low	1	0
sgx 523	1	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent	2013	2013	11.0	low	1	0
bms 777607	1	aromatic amide		2013	2013	11.0	low	1	0
sgi 1776	1	imidazoles		2013	2013	11.0	low	1	0
pci 32765	1	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
ponatinib	1	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
amg 900	1			2013	2013	11.0	low	1	0
mk-1775	1	piperazines		2013	2013	11.0	low	1	0
bag956	1			2013	2013	11.0	low	1	0
quizartinib	1	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor	2013	2013	11.0	low	1	0
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester	1	carbamate ester		2013	2013	11.0	low	1	0
tak 733	1			2013	2013	11.0	low	1	0
mk 2206	1	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	1	0
navitoclax	1	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	2013	2013	11.0	low	1	0
sns 314	1	ureas		2013	2013	11.0	low	1	0
jzl 184	1	benzodioxoles		2013	2013	11.0	low	1	0
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	1	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
dcc-2036	1	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
cabozantinib	1	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
incb-018424	1	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	1	0
bix 01294	1	piperidines		2013	2013	11.0	low	1	0
pf 3845	1	piperidines		2013	2013	11.0	low	1	0
gsk 2126458	1	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent	2013	2013	11.0	low	1	0
ixazomib	1	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor	2013	2013	11.0	low	1	0
ldn 193189	1	pyrimidines		2013	2013	11.0	low	1	0
plx4032	1	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor	2013	2013	11.0	low	1	0
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol	1	biphenyls		2013	2013	11.0	low	1	0
gsk 1363089	1	aromatic ether		2013	2013	11.0	low	1	0
kin-193	1	pyridopyrimidine		2013	2013	11.0	low	1	0
bay 869766	1			2013	2013	11.0	low	1	0
baricitinib	1	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent	2021	2021	3.0	low	0	1
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester	1	carbamate ester		2013	2013	11.0	low	1	0
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2013	2013	11.0	low	1	0
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline	1	benzenes; sulfonamide		2013	2013	11.0	low	1	0
cp 466722	1	quinazolines		2013	2013	11.0	low	1	0
CAY10626	1	ureas		2013	2013	11.0	medium	1	0
thiopental sodium	1	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor	2013	2013	11.0	low	1	0
pf 3644022	1			2021	2021	3.0	medium	0	1
pha 793887	1	piperidinecarboxamide		2013	2013	11.0	low	1	0
nvp-bsk805	1			2013	2013	11.0	low	1	0
xmd 8-92	1	pyrimidobenzodiazepine	protein kinase inhibitor	2013	2013	11.0	low	1	0
jq1 compound	1	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer	2013	2013	11.0	low	1	0
jnj38877605	1	quinolines		2013	2013	11.0	low	1	0
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide	1	benzothiazoles		2013	2013	11.0	medium	1	0
gsk2292767	1			2021	2021	3.0	medium	0	1
torin 1	1	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor	2013	2013	11.0	low	1	0
ly2940680	1			2013	2013	11.0	low	1	0
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea	1	ureas		2013	2013	11.0	low	1	0
ro 4929097	1	dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound	EC 3.4.23.46 (memapsin 2) inhibitor	2013	2013	11.0	medium	1	0
gsk4112	1			2013	2013	11.0	low	1	0
torin 2	1	aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline	antineoplastic agent; mTOR inhibitor	2013	2013	11.0	low	1	0
pf-4708671	1			2013	2013	11.0	low	1	0
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide	1	benzamides; N-acylpiperidine		2013	2013	11.0	medium	1	0
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	1	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes		2013	2013	11.0	medium	1	0
belinostat	1	olefinic compound		2013	2013	11.0	medium	1	0
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate	1	carboxylic acid; pyrroline		2013	2013	11.0	low	1	0
a 769662	1	biphenyls		2013	2013	11.0	low	1	0
LimKi 3	1	1,3-thiazoles; dichlorobenzene; organofluorine compound; pyrazoles; secondary carboxamide	LIM kinase inhibitor	2013	2013	11.0	low	1	0
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone	1	pyrroles		2013	2013	11.0	medium	1	0
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole	1	dipyrrins		2013	2013	11.0	medium	1	0
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide	1	tryptamines		2013	2013	11.0	medium	1	0
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione	1	pyrazines		2013	2013	11.0	medium	1	0
gsk837149a	1			2013	2013	11.0	low	1	0
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide	1	quinazolines		2013	2013	11.0	medium	1	0
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide	1	quinazolines		2013	2013	11.0	medium	1	0
wnt-c59	1			2013	2013	11.0	low	1	0
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime	1	indanes		2013	2013	11.0	medium	1	0
ar-12286	1			2021	2021	3.0	medium	0	1
chir 258	1			2013	2013	11.0	low	1	0
osi 027	1			2013	2013	11.0	low	1	0
hli 373	1			2013	2013	11.0	medium	1	0
pemetrexed	1	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor	2013	2013	11.0	low	1	0
sildenafil citrate	1	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent	2013	2013	11.0	low	1	0
aprepitant	1	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist	2013	2013	11.0	low	1	0
xav939	1	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor	2013	2013	11.0	low	1	0
2-carboxyarabinitol 1-phosphate	1			2013	2013	11.0	low	1	0
nintedanib	1			2013	2013	11.0	low	1	0
bay 65-1942	1			2021	2021	3.0	medium	0	1
ver 52296	1	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor	2013	2013	11.0	low	1	0
sb-590885	1	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound		2013	2013	11.0	medium	1	0
pf-477736	1			2013	2013	11.0	low	1	0
fenobam	1	ureas		2013	2013	11.0	low	1	0

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
3-hydroxybutyric acid	1	(omega-1)-hydroxy fatty acid; 3-hydroxy monocarboxylic acid; hydroxybutyric acid	human metabolite	2009	2009	15.0	low	1	0	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	2	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector	2019	2021	4.0	low	0	1	1
triiodothyronine	1	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone	2021	2021	3.0	low	0	0	1
7,3'-dihydroxy-4'-methoxyisoflavone	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	antioxidant; metabolite	2019	2019	5.0	low	0	1	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
Alloxan Diabetes	1	2019	2019	5.0	low	0	1	0
Anoxemia	1	2016	2016	8.0	low	0	1	0
Autoimmune Disease	1	2021	2021	3.0	low	0	0	1
Autoimmune Diseases	1	2021	2021	3.0	low	0	0	1
Benign Neoplasms	1	2009	2009	15.0	low	1	0	0
Cardiac Failure	1	2016	2016	8.0	low	0	1	0
Cirrhosis	1	2019	2019	5.0	low	0	1	0
Congenital Zika Syndrome	1	2020	2020	4.0	low	0	1	0
Diabetic Glomerulosclerosis	1	2019	2019	5.0	low	0	1	0
Diabetic Nephropathies	1	2019	2019	5.0	low	0	1	0
Disease Models, Animal	2	2017	2020	5.5	low	0	2	0
Fibrosis	1	2019	2019	5.0	low	0	1	0
Genetic Predisposition	1	2016	2016	8.0	low	0	1	0
Glial Cell Tumors	1	2015	2015	9.0	low	0	1	0
Glioma	1	2015	2015	9.0	low	0	1	0
Heart Failure	1	2016	2016	8.0	low	0	1	0
Hypertension, Pulmonary	1	2016	2016	8.0	low	0	1	0
Hypertrophy, Right Ventricular	1	2016	2016	8.0	low	0	1	0
Hypoxia	1	2016	2016	8.0	low	0	1	0
Inflammation	1	2019	2019	5.0	low	0	1	0
Injury, Myocardial Reperfusion	1	2021	2021	3.0	low	0	0	1
Innate Inflammatory Response	1	2019	2019	5.0	low	0	1	0
Interstitial Nephritis	1	2019	2019	5.0	low	0	1	0
Neoplasms	1	2009	2009	15.0	low	1	0	0
Nephritis, Interstitial	1	2019	2019	5.0	low	0	1	0
Osteogenic Sarcoma	1	2017	2017	7.0	low	0	1	0
Osteosarcoma	1	2017	2017	7.0	low	0	1	0
Pulmonary Hypertension	1	2016	2016	8.0	low	0	1	0
Right Ventricular Dysfunction	1	2016	2016	8.0	low	0	1	0
Zika Virus Infection	1	2020	2020	4.0	low	0	1	0

Bioavailability (1)

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019